Genmab at bank of america global healthcare conference: late-stage push

Genmab, during the Bank of America Global Healthcare Conference, presented its ambitious plan to expand its oncology portfolio through several late-stage assets. The main focus was on petosemtamab, Rina-S, and EPKINLY, which form a standalone growth franchise for the company. Management highlighted that these assets are expected to launch in late 2027, assuming positive data and approvals.

Petosemtab, which is now in expanded Phase III trials for colorectal cancer and locally advanced head and neck cancer, has shown promising results in Phase II data. The company expects Q4 2026 readout to focus on the objective response rate, with survival data following later. Rina-S, acquired in 2024, has expanded to include five active Phase III trials, including trials for platinum-resistant ovarian cancer, endometrial cancer, and platinum-sensitive maintenance ovarian cancer.

Management pointed out that higher development spending and future amortization costs could negatively impact reported earnings. The company's second-quarter 2026 results were strong, driven by better-than-expected top-line growth, mainly from Darzalex and EPKINLY. The company is transitioning from a partnership-based model to an integrated biopharmaceutical entity with its own commercial capabilities. Despite rising R&D costs and SG&A expenses, Genmab remains optimistic about its future pipeline.